<SEC-DOCUMENT>0001104659-14-051641.txt : 20140715
<SEC-HEADER>0001104659-14-051641.hdr.sgml : 20140715
<ACCEPTANCE-DATETIME>20140715170809
ACCESSION NUMBER:		0001104659-14-051641
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140714
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140715
DATE AS OF CHANGE:		20140715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xencor Inc
		CENTRAL INDEX KEY:			0001326732
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				201622502
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36182
		FILM NUMBER:		14976455

	BUSINESS ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		626-305-5900

	MAIL ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a14-17167_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> July&nbsp;14, 2014</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">XENCOR,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-36182</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20-1622502</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File No.)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">111 West Lemon Avenue</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Monrovia, California 91016</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:<b> (626)&nbsp;305-5900</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-ba.htm',USER='108699',CD='Jul 15 09:06 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Departure of </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Directors</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Effective as of July&nbsp;14, 2014, the Board of Directors (the &#147;Board&#148;) of Xencor,&nbsp;Inc. (the &#147;Company&#148;) appointed Kurt Gustafson as a director of the Company. In addition, Mr.&nbsp;Gustafson was appointed to serve as chairman of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with Mr.&nbsp;Gustafson&#146;s appointment, the Company granted to Mr.&nbsp;Gustafson an option to purchase shares of the Company&#146;s common stock pursuant to the Company&#146;s 2013 Equity Incentive Plan under its current compensation practice for newly appointed non-employee directors. Mr.&nbsp;Gustafson will receive a cash retainer consistent with the Company&#146;s current compensation practice for non-employee directors. The Company also anticipates that Mr.&nbsp;Gustafson will enter into the Company&#146;s standard indemnification arrangement for officers and directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with Mr.&nbsp;Gustafson&#146;s appointment to the Board, and the promotion of John R. Desjarlais, Ph.D., to Senior Vice President of Research and Chief Scientific Officer, the Company issued a press release on July&nbsp;15, 2014, a copy of which is attached hereto as Exhibit&nbsp;99.1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)&nbsp;Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="89%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:89.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:89.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   Release dated July&nbsp;15, 2014.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_084927_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-ba.htm',USER='108699',CD='Jul 15 09:06 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   July&nbsp;15, 2014</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">XENCOR,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:   </font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Bassil I. Dahiyat, Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bassil I. Dahiyat, Ph.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_085219_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-ba.htm',USER='108699',CD='Jul 15 09:06 2014' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="89%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:89.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:89.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   Release dated July&nbsp;15, 2014.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_085302_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-ba.htm',USER='108699',CD='Jul 15 09:06 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a14-17167_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="252" height="79" src="g171671mmi001.gif"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Xencor Appoints Kurt Gustafson to Board of Directors;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Promotes John Desjarlais to Chief Scientific Officer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MONROVIA, Calif., July&nbsp;15, 2014</font></b><font size="2" style="font-size:10.0pt;">&#151; Xencor,&nbsp;Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors.&#160; Mr.&nbsp;Gustafson will also serve as chair of Xencor&#146;s audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R. Desjarlais, Ph.D., to senior vice president of research and chief scientific officer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Kurt brings a tremendous amount of experience and a fresh perspective to the board as we grow our company and expand our drug development efforts,&#148; said Bassil Dahiyat Ph.D., president and CEO of Xencor. &#147;His expertise in biotechnology and finance will be of particular value as we advance our drug development programs and evaluate additional opportunities for partnering and licensing our technology.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Gustafson has more than 20 years of industry-related experience. Currently, Mr.&nbsp;Gustafson serves as executive vice president, chief financial officer and principal accounting officer at Spectrum Pharmaceuticals,&nbsp;Inc. Prior to that, he served as chief financial officer at Halozyme Therapeutics,&nbsp;Inc., and before that he had a long career at Amgen in various financial and planning roles, most recently as vice president, finance. He earned a B.A. in accounting from North Park University in Chicago and an M.B.A. from University of California, Los Angeles.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;John has driven the company&#146;s technology development and engineering efforts for the past eight years,&#148; said Dr.&nbsp;Dahiyat. &#147;In addition to his critical involvement in our clinical-stage antibody programs, John has played a key role in the creation of our entire XmAb technology and pipeline, including our new bispecifics programs, which we are beginning to advance into development.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Desjarlais joined Xencor in 2001and was promoted to vice president of research in 2006, where he oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates. Prior to joining Xencor, Dr.&nbsp;Desjarlais was an assistant professor of chemistry at Penn State University. Dr.&nbsp;Desjarlais received a B.S. in physics from the University of Massachusetts and a Ph.D. in biophysics from Johns Hopkins University. He conducted postdoctoral research at the University of California, Berkeley.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Xencor,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor&#146;s XmAb&#174; technology. Xencor&#146;s internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in Phase 1 development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor&#146;s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&amp;D LLC, Alexion and Boehringer Ingelheim.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For more information, please visit www.xencor.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-mm.htm',USER='108699',CD='Jul 15 09:02 2014' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statements contained in this press release regarding matters that are not historical facts are &#147;forward-looking statements&#148; within the meaning of the U.S. securities laws, including statements associated with Xencor&#146;s research and its expectations regarding future therapeutic and commercial potential of Xencor&#146;s technologies, programs, drug candidates and intellectual property related to Xencor&#146;s XmAb technology.&#160; Because such statements are subject to risks and uncertainties, including risks associated with the process of discovering, developing and commercializing drugs that are safe and effective, actual results and the timing of events may differ materially from those expressed or implied by such forward-looking statements.&#160; These and other risks concerning Xencor&#146;s programs and technology are described in additional detail in Xencor&#146;s SEC filings.&#160; These forward-looking statements speak as of the date on which they were made, are based upon Xencor&#146;s current expectations and involve assumptions that may never materialize or may prove to be incorrect.&#160; Xencor disclaims any intention or obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Contact:</font></b><font size="2" style="font-size:10.0pt;"><br> Xencor</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">John Kuch, Vice President Finance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">626-737-8013</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate Communications Contact:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canale Communications</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jason Spark</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">619-849-6005</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108699\14-17167-1\task6865854\17167-1-mm.htm',USER='108699',CD='Jul 15 09:02 2014' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g171671mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g171671mmi001.gif
M1TE&.#=A_`!/`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````_`!/`(?___\`<YP`8Y0`<XP0<Y3O]_<`C)0II:52C*5[K:5[:Z7F[YQ*
M*>9[2J7FSIQ*".9[C*52K;5:SJ6$Q=8AA)RMI<X0G,X0SJ7>SL[>[\XQC*5"
M:Z5:SMX`G)SFI>][*>;FI:VUI6NU0N^U0FNUI2FU0JVU0BGF<^_F<ZVU<VNU
M$.^U$&NU<RFU$*VU$"E:[^9"2J7FI<Y[".;FI8RUI4JU0LZU0DJUI0BU0HRU
M0@CF<\[F<XRU<TJU$,ZU$$JU<PBU$(RU$`A[SJ7>WN\`8XR$:V,Q:V,Z[V.$
M6C$ZWC&$&3$ZG#&$*6,ZK6.$[Z5:6C$0WC%:&3$0G#%:[Z5::V,0[V-:*6,0
MK6,0[]X06C%CWC$0&3%CG#%C[V,0*6-CK6-:C-XQSMXQ6A"$WA`Q&1"$G!"$
M2F,Q2F,ZSF.$"&,ZC&-:2F,0SF-:"&,0C&-CSF,0"&-CC&,`I:W.WN\0:[6M
MI:WFI6L0:^;F0N_F0FL00N_FI2GF0JWF0BD00JVMI>^M<^^M<ZWF<VOF$._F
M$&L0$._F<RGF$*WF$"FMI8SFI4KF0L[F0DH00L[FI0CF0HSF0@BM<\ZM<XSF
M<TKF$,[F$$H0$,[F<PCF$(SF$`A[M<40$)2$[^8QG.\Q[Z40G.\0[Z6EYM:]
MYMX00HR$[V,Q[]XQ6C&$WC$Q&3&$G#$Q*6.$K6,(:V.$SF,Q"&.$C&.<SM:U
MSM8QG,6MWO<QQ:4`4GM*:^^U[VNU[RE**;5*2N^USFNUSBE*"+5*:\ZU[TJU
M[PA**91*2LZUSDJUS@A*")00$+5:K<5:K>^$E.^$:Q`Z[Q"$*1`ZK1!::Q`0
M[Q!:*1`0K1`0SN\0:Q!C[Q`0*1!CK1"$E,Z$2A`ZSA"$"!`ZC!!:2A`0SA!:
M"!`0C!`0SLX02A!CSA`0"!!CC!![:^_F[VOF[RE[*;6M[ZU[2N_FSFOFSBE[
M"+6MSJU[:\[F[TKF[PA[*92M[XQ[2L[FSDKFS@A[")2MSHQ2K9P(2EJ$M>_.
M[^__WO<`>YS__^\(_P`!"!Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FQ0+X-S)L^?$6`@H;#@V
MQZ?1HT=A":A%A$@M`K&02ITZ<X[3``(".*6@DZK7KR<+(""2=0`1K:-@@5W+
M]J.F6@(&:`U@ELBQMGCS5IPC@.R`N(!K(=!+N/#"`AK@_IW;E$A4PY`C`WC;
MN*G9I1HD:T8Z!Y;GSZ!A59@PJG%<LDT)#-G,FN?;6K5&Q9XM&S:1NI6;UIK0
MNK?-UP+ZYB:KM2GCQH)]*Y<Y9&F`YP$H$(A.0'KUZW3/+B7`;Z*H.7/XA?\'
MWUVB^/'GRR\W/*%6``00-,6/GT#3M?IU-,D/FEW`XX@%R$+`@`0&`%5$L`QH
MH((#J+7>6J'`$DI!;Q%P3`7N8%A!+!NZPV$L=<0"(@(:$$`$`;-0Q`\%9\E%
M%U:B/+1BBR\2@4!7#U)50`0&]!A!C`+!`I<&""`@GWP00'`,!/`M68$H^VE%
MP6H_O6CE`%PU)%96T-&598Y>\6B`'!V,"60!%#!5'05L:L#F!FRR622&FI"X
MU&`4:2*7B\\)H`&.">GYXIX!.`CF5!,8T($<9,JA:%>QP";<<)5%A\"&3$Y7
MBR8Y:?`<H5K=I5`L71KPJ:B'2L5/!XO*08LL9!K_P*E`LR!PG72X#HAK:@AX
MF&E3%:A(@8NF/D<$;PBAZ:*+1/R9JE0[CBG',:%,$&L$!1703P'<=NMM`=?`
M10`"'!:I%0%%300+C8,&\!]!`9YU90!`/GN4)F->$`$L<P@1*ZKP*O3/,7!1
M`$$L[O!7RY<2'0.JB^@:M"ZQG\YJKU&SL"I'!!.($@JL9=8+$9H%7S.B=+4<
M\\]$B!%1[*#.#B0*EU?>>+%1T;JJB2BB<,"J`0!'-(2)1%"@R<E$C&)Q1/Q,
M)]?+1$30%6++?AJ`>@YQRP\_W';$-:`2:=TU1CI]#;9%W49TC*+3AC+'!#]+
M;5$%C6W@X35!G?@N1!/(_\NG5K-&P.4`ILIE*$/\Q!*!FP3008$&^V)]T+=I
M"U0`+!'`^7@$L9RM4&>+N_FX+!/L[5#BQP05IRS'=,P0Y3C.<4R)&B#;D"BM
M2@"+QQ&4V8'(>3(5P`9TVOH4E1)%4+6+_L525I=19PT+!<$%]V)?`ACMN4":
MM/DX!:+&HH%Q?09'P>$)\7.,B=5G)5P`&L"RO4'\=%\]5E@U1H`LI@\4X/=N
M$M4$V*>5S&A)`XOBF"AF$8%8H:]3[AG`I6+!I``(9GX*09/+H$.Q+NV)89]#
M@/4\"+VBI>@@@G.?5K"E%)K]+2M+.T@L6%0J$I(E`I([R/2(\S(.TH4``CB&
MY__F<)G\84L3MX&.C3`X$`F,Z0`<"(4H)G"!,F%+(T-(TUD2@"D$6#!H#YF#
MU0I'0C[UCW[#@HX!GM8N8SGF(,>05Y\XAQ4R/F>-G[)+0B8P%ZNI\6_-0IY!
M"H#$P?D0CQQL5KH(LJ(N"6!?<MR3+&[G#SGH2XJQ.("C#L#$B$2J+P0X6L(V
M8,$S,J1O?K12L08P`#`>9$6&].$=U9@5T\7Q2A3`GQJM9"7'G&U=\EHE+P,`
MM9@9Y)9EI$LLC44!R37-C[E4)5WPE,$#)'`"<Q!%`WLTH8Y0IF@A@H47GV+*
MA2"`E;/THP'\U$D`1(!=>T*G6=IHH$4*Y):(G"4KS<+_)V&"$`!S`*(P"<7/
M-NK1(*C<DS_9A,YV"8":`ED1&U,YSUIP<B''6!048R&*8S#*`+;K"`+$=:DZ
MV,J"QAQ9-`GJ1WL&BF9D1$#I(G0,&EIM`+)8V4"\2$)E4H!U7GS8IPZ'&%G*
M!0%N@U(NJT87EXHBB234Q-8*D#A9H/-E`UC:T&3Y*2RQ[A@/+`CN$BC%"=#"
MBB$A6?:*Y*F^I(4BH1@F(H^E)3HLCP[=9*3RB%FC=SD,5"^2JLRL.LR#"B06
M@#5<MH[QHI@2Y!^RB.0/@1>D>=73?VE<'@4FT$Z!'(`"KNH8+&CAJ`[DD",!
M#0X0*Y.</#W/@U=D"!()2@#*_UIN?!XT)C+M&-9SWG%/U$0,E\B85PK)T4OJ
M<5YC?WA:@21TE:AZ9CH'H('F(B11BZ)%+#[F*`,4%R1":@QNB+"!SA[D`$\C
M%!%BF"P-3#0`[&5D&P50+X?QLI4(X4<JH].56<QKO0H9WSZU8BC[6DD`(3V(
M;Z&3O>YP*XWM<NE"^'$`:<F"`YID57P[$E"XH.8L3G&E0Y1;PP&@2*<)$04)
MF[F0=_*5+A9#YIZXDQ">$BIF2+SI/RG$)L?E<E9H$@!6+ZJ04#S/18\1HQ\'
M$%N'X$Y1K(JR`8@LDI%^.#"U99FR;JK$E.J07428Y$(0:[7L"61@MWD91`TB
M*`83^?^<;'PD!JFZM:F61XQ5`_!A(&RJ@S:23P((:Y%[%.6?+<JV'-%$:4ZC
M%>%LN"&1W2_A0M5B0S)91+&`1:8WK>E8,!:779,Q79J,4(72Q5EHZA)=!-V0
M=:7RNP@1'`<E&-'I$'-/$CY,A<>TJ$7UR`"YUD@LFL+H)"[,O`696#I[2&"%
MR**QS,.?^Z:MZBX]YJ]*%/-U><E.`.B7J>5<R`0H)A=!!@JP64KUWQ"MD(SQ
MFE&]GC*R9;0!IBSF-L()=T(":M1YF;BY_\!M3X=)0CRZR$$R-D#T]NBWYSAK
M%@V7BW5E"\\='P255F,QOP=%@6`O!!9L8Q2\K3COAA`,*W+_26*(<^);/H'J
M90_UG%B61]%V_:U81$`X5)^SYH*,FY=94O%$.UX144=GX@/Y^2KI\#4(N\CC
M+0ZYR,L$THZ$%\3*;`H%4!P13<#T11&XI:D%$-]XO9B,\K0Y75*>'9WSE96D
M]GF:7V1`4OF0Q7G:X*<LCE`:R87%^M7GU7)B39%/G9L;Z3"CY^D4?2-$Q0;-
MDGNK[:Y!PAF:!#"`=#1/!\UG/I>;ETZA[ME0K6C;(/_XN9MU(O0KG7`B&.<3
MU)/^MZ-[>ZG0R3)<I7[X`Y@[)_7."HC_LO*)\$/@PNQFTUB*I;,=P]+'V-H0
MMA8>4=1Y^M07SU3O&?&X$R2AGW)6_^!ORFZ&N+IJY1]('`E*@5KK>/;B[C4X
MIEXF*E>DD/-D^[$I(G:K&18`L/!>I@<V@E(LCV01:&8E^Z,0`3A+W08`+#)7
M"081K8=S$ZA@P61ZEH-[T`%_46=X(R<K%Q$IQL%X=>%X,I2!X6<0+D90#5(0
MI%(U?.<0HF8C"@%^="$+71%I7>5]>H4`$1"$1F(YMK8LI_=X2S8`R#($/D0X
M'IA!&M,!\P=OBL)JAT$R?J$=9J$TPN)R+R)A5)-.9[%(#\9M5@@`0Q`:FJ9^
M9T%&/NA<I5<T7?%S@`9UZ](^V=,5!C9CZ==F9A11:50LNF<1H:`Q(.@[2)<0
M!%,697$6^_\7-K)V)4J($'BF:M0%*#Q8.`:4+)%%%L'1+#OU-SAU@WZS3ILH
M"K8V*&\89-`36\,FAB(F$!NW+)LH72]"8QBA"89(?P;@90TQ-(KQ*8&1?@QG
M63U'$+"@=O_7>LP3B[,%/05F<\=(>W_#,&/Q8A:D"9[S?'D64I.W+'0U.4$U
M2^$(`%LF>QE1`(5'?[XC-Q#Q2110)-1C%IM"$:FU2UB"="Z&5947BDL6?04Q
M!RYV4[IU7$Q&B@1)$+/04,P3`?8T!PNV2G@G$$9F5`\$D39D3!NW=Z]W$050
M:(WB.P80=D%8DB89A,=0+P%5-+!@4EA1"[YX0#07:*^#6Z""B][_9EE%$P&:
M,`&:$`$FLDM8X5>F%F8)D7KO!4+]IT3O<0P_N5+^!T9[!6@/M3O9U#UM)!?%
MI6ZW2(P/$0I0)F6%-I9CJ2@]8COUM@$(<`WN=2*_YQ`YAHT'V1#?ID\'F'0J
MB!78,T(V1VH+MG9O"``X.(KP,GEOET?$5D8[-B-DU&<","!\*4P)-GY6DX@0
ML39C"8*:>8B(=WLG(AU.<8$-87=Y-H,2`UB`0Q#8AIHU9"Q>9E_,,XU!HEE@
M<WQ"56UL9$*4:%,$QV5KQUX2-6F7M1'_L&N-(@<'\"JT$(2T<`P1(`'.&0&O
M<BT#`9%.`1N/-F$"QTM>21`#B7ZJ:9"-_^F"-E,0R$1,=XD0<;F"EK<LJU0X
MJV1"7%<0LY!97":<V7$^![%58_2$,E)A(L<QV[5=H3`+H7"@!AHAH2`!9'(`
MZG$Y$8``9Z@0[Q07\J1G(R-@:W<N@C1#MR&*_A<`0H1"'UH71RAW^_07%D=(
M-E5[:_=(B;@C&XJ-7853P58`V9%R].41O<,H$I!4L_`=HA`+0<I1!9II'M4!
M]H<1,_0XGR4Z[A@1<_"DCR,Z"49(GL)/K)1$!/`C@?(]LO`XV3D]8$H!44H_
M6*FEMW$6_/..85H76\I*75I.Q_=38&J9$%&(C+(O0>J3T'D,?\H!T2D+I.4H
M@:EEL(,VL"-SG>+QDRAY#+$0HY1SA=_R.E,4G6$W`1F@(K#@J&$'5NU$.?\P
MGQ?!#P':,5-4J(97J!=P>!30G3<3JPS1H[0P`65%A9I'=;^VJQT@FK+ZJPX!
M"XPB"Q(0J:-5?R>9K&$'J\#:K`-AJI;$IZ&P30;0D<YZK1C1HZ3#,TE:==CZ
MK:5*)L3*,V:U2:0*KNCJ9-D%"[/@#J2E*'B:KO(Z$/_`*+4Z`;#B*+XZK_S*
M@F,B"ZUJJ.?:KP3+2-8DEOY9L/+*#[W#*@C`K`H[K]D4KQ%;L19[L1B;L1J[
..L1S;L1[[L2"+K0$!`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
